Floatz logo

Vinorelbine

Breast Inflammatory Carcinoma

M.D. Anderson Cancer CenterPhase 2Dormant
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

11 Active assets in the Breast Inflammatory Carcinoma cohort.

Asset / SponsorPhaseRating
Trastuzumab Emtansine
Hoffmann-La Roche
Phase 3BB
Inno-206
M.D. Anderson Cancer Center
Phase 2B
Olaparib
National Cancer Institute (NCI)
Phase 2B
Pembrolizumab
Northwestern University
Phase 2B
FLUTICASONE
Academic and Community Cancer Research United
Phase 2B

View all 12 →

Same molecule, other indications

Vinorelbine is also rated in:

HER2 positive breast carcinomaDormant
BBB
Indicative ·
74 / 100
View asset →
Recurrent Breast CarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
Hodgkins lymphomaDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →